Boston Scientific Corp. has acquired private firm and maker of FDA-approved fallopian tube cell collection device, Nvision Medical Corp., in a deal worth $275 million. The sale will include a $150 million cash payment and up to $125 million in clinical and commercial milestone payments across the next four years. The acquisition is not expected to impact Boston Scientific's bottom line through 2018 and 2019.